Key result
ACURATE neo2 TAVI yields mild or no paravalvular leak in ~99% of patients at 1 year.
Why the study?
Complications related to paravalvular leakage after transcatheter aortic valve implantation persist, impacting mortality and rehospitalisation risk.
Does the ACURATE neo2 transcatheter heart valve demonstrate favorable safety and valve performance at 1 year in patients with severe aortic stenosis?
Cohort
Does the ACURATE neo2 transcatheter heart valve demonstrate favorable safety and valve performance at 1 year in patients with severe aortic stenosis?
The ACURATE neo2 transcatheter heart valve demonstrates favorable safety and valve performance, with 99% of patients having mild or no/trace paravalvular leakage at 1 year in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Supports favorable paravalvular leakage outcomes with ACURATE neo2 in routine practice; hypothesis-generating pending randomized confirmation.
Kim et al. (2023) conducted a cohort in severe aortic stenosis. ACURATE neo2 valve was evaluated on mild or no/trace paravalvular leakage (PVL). Transcatheter aortic valve implantation using the ACURATE neo2 valve resulted in 99% of patients having mild or no/trace paravalvular leakage at 1 year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: